

# QuickView

## Zeltia

## Charting a course into clearer waters

Zeltia has made significant progress in weathering the storms of recent years. FY13 results demonstrate improved profitability and cash flows, which have further reduced the debt burden. Ex-US ex-Japan Yondelis sales have resumed their growth trajectory (net revenues up 10% to €73m) following the resolution of Doxil supply issues in May. Looking forward, clinical data in H214 for Zeltia's two key products could be transformative. Janssen's 2015 FDA filing of Yondelis rests on positive Phase III sarcoma results, while Taiho could file in Japan by year-end on the back of its pivotal Phase II study. Full data from the Phase II PM01183 study in ovarian cancer could form the basis of a lucrative licensing deal.

### Yondelis: Expecting key data by year-end

Janssen's 586-pt US <a href="Phase III">Phase III</a> study in L-sarcoma completed recruitment in December and is expected to render results in H214. Positive data would support an FDA filing in 2015 and trigger payment of \$20m of milestones to Zeltia (\$10m development; \$10m on approval). Pivotal data from the Taiho soft tissue sarcoma (STS) study should support Japanese filing in H214 (milestone due on approval).

### PM01183: A promising second-generation compound

Top-line Phase II platinum resistant/refractory ovarian cancer (OC) data from the open-label comparator study showed median progression-free survival for the total population of 4.8 mths for PM01183 vs 1.7 mths for topotecan (p=0.0004). 30.3% of pts had an objective response (OR) to PM01183 vs none on topotecan; clinical benefit (OR + stable disease) was 82% for PM01183 vs 50% for topotecan. Overall survival data will be available this year (potentially at a major cancer congress) and could secure a partnership. Three pivotal Phase III OC trials should start H214-H115.

## Financials: Biopharma back on course

The European Doxil shortage (Q311-Q213) weighed on FY12 results. Revenue growth in FY13 (3% to €142m) was driven by the 9% improvement in biopharma sales to €79m. EBITDA increased 16.6% to €23.8m; EBITDA margin benefited from the greater contribution of the higher-margin biopharma segment and ongoing cost controls. Net profit rose 72% to €11.3m, which coupled with positive operating cash flow of €16.1m contributed to a c 20% decline in total debt (net debt: €64.6m).

## Valuation: Catalysts to drive upside

Zeltia's share price has doubled in the past 12-months; however, potential upside remains from near-term clinical/regulatory catalysts, and the prospect of licensing.

Consensus estimates						
Year end	Revenue (€m)	PBT* (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/12	138.2	9.4	0.08	0.0	N/A	N/A
12/13	141.8	13.8	0.10	0.0	N/A	N/A
12/14e	160.0	21.4	0.11	0.0	N/A	N/A
12/15e	172.4	25.0	0.14	0.0	N/A	N/A


Source: Company accounts, Bloomberg. Note: \*PBT represents continuing operations.

Zeltia is a research client of Edison Investment Research Limited

#### Pharma & biotech

5 March 2014





Share details	
Code	ZEL
Listing	Madrid
Shares in issue	222.2m

#### **Business description**

Zeltia is a Spanish biopharmaceutical group with a core focus on the development of marine-based drugs for cancer. Its only marketed product, Yondelis, is approved in the EU and partnered with Janssen (J&J) in the US. The group also has subsidiaries active in consumer chemicals, molecular diagnostics and RNAi technology.

#### Bull

- Growing cancer pipeline with novel mechanisms of action
- Approx \$30m of J&J/Taiho milestones for Yondelis may fall due in 2015.
- Phase III US Yondelis data, expected in H214 (STS) and H118 (OC), could lead to US approval.

#### Bear

- Protracted licensing process for PM01183.
- Potential Yondelis regulatory delay(s).
- Macroeconomic climate and/or adverse weather conditions hold back consumer chemicals.

# **Analysts**Lala Gregorek +44 (0)20 3681 2527 Dr Mick Cooper +44 (0)20 3077 5734

healthcare@edisongroup.com

EDISON QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (<a href="https://www.fsa.gov.uk/register/firmBasicDetails.do/sid=181584">www.edison.fivestment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [4608569] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. <a href="https://www.edisongroup.com">www.edisongroup.com</a>.

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Zeltia and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research and prote be eligible for sale in all jurisdicions or to certain categories of investors. This research is issued in Australia Dy Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment advisers Act of 1940 and corresponding state securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities along the Exchange Commission. Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed to a feet and the information provided by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, or attempt to effect, or attempt to executive securities mentioned or in the topic of this document. Edison has a restrictive policy related for New Zealand resident professiona